Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 9, 2010
Wed, December 8, 2010
Cubist Pharmaceuticals to Present at December Investor Conference
LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that Michael Bonney, President and CEO, will present on Wednesday, December 15, at 9:30 a.m. Eastern Time, at the 2010 Deutsche Bank BioFEST Conference being held at the Four Seasons Hotel in Boston. The webcast presentation will include a discussion of the companya™s business activities, financial outlook, and current news.
This presentation will be accessible live through Cubista™s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section and will remain available there for a period of 30 days after the presentations.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
